Are monocytes a preferable option to develop myeloid cell-based therapies for solid tumors?
Journal of Experimental & Clinical Cancer Research,
Journal Year:
2025,
Volume and Issue:
44(1)
Published: March 15, 2025
Abstract
In
the
last
two
decades,
novel
and
promising
cell-based
therapies
have
populated
treatment
landscape
for
haematological
tumors.
However,
commonly
exploited
T
NK
show
limited
applicability
to
solid
This
is
mainly
given
by
impaired
tumor
trafficking
capability
effector
activity
of
these
cells
within
a
highly
immunosuppressive
microenvironment.
Myeloid
spontaneously
home
tumors
can
thus
be
reprogrammed
and/or
engineered
directly
attack
or
locally
selectively
deliver
therapeutically
relevant
payloads
that
may
improve
efficacy
immunotherapy
against
difficult-to-access
context
myeloid
therapies,
adoptive
transfer
monocytes
has
often
been
overshadowed
infusion
differentiated
macrophages
hematopoietic
stem
cell
transplantation
despite
their
therapeutic
potential.
Here,
we
summarize
recent
improvements
benefits
using
tumors,
current
clinical
applications
challenges
use
as
well
some
possible
strategies
overcome
them.
Language: Английский
CAR-NK cell therapy: a potential antiviral platform
Ming-Hao Lin,
No information about this author
Lijuan Hu,
No information about this author
Jeffrey S. Miller
No information about this author
et al.
Science Bulletin,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
Language: Английский
Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma
Sijia Yan,
No information about this author
Xi Ming,
No information about this author
Rubing Zheng
No information about this author
et al.
Cancer Medicine,
Journal Year:
2025,
Volume and Issue:
14(6)
Published: March 1, 2025
ABSTRACT
Background
As
a
rapidly
developing
therapeutic
method,
targeted
therapy
plays
an
important
role
in
the
treatment
of
multiple
myeloma.
In
recent
years,
mature
B
cell
antigen‐targeting
has
brought
new
hope
for
patients
with
refractory/relapsed
disease.
While
increasing
number
relapse
are
exposed
to
this
type
drug,
changing
target
may
be
effective
strategy
relapse/refractory
Objectives
The
expression
G
protein‐coupled
receptor,
class
C
Group
5
member
D
(GPRC5D),
on
surface
myeloma
tumor
cells
makes
it
possible
therapy,
and
relevant
studies
progress.
Results
&
Conclusions
review
aims
systematically
summarize
current
advancements
GPRC5D‐targeted
therapies
myeloma,
thereby
providing
valuable
insights
foundation
future
studies.
Language: Английский
The Improving Outcomes in Relapsed-Refractory Diffuse Large B Cell Lymphoma: The Role of CAR T-Cell Therapy
Vibor Milunović,
No information about this author
Dora Dragčević,
No information about this author
Martina Bogeljić Patekar
No information about this author
et al.
Current Treatment Options in Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 28, 2025
Language: Английский
Trogocytosis in CAR immune cell therapy: a key mechanism of tumor immune escape
Yizhao Chen,
No information about this author
Qianling Xin,
No information about this author
Mengjuan Zhu
No information about this author
et al.
Cell Communication and Signaling,
Journal Year:
2024,
Volume and Issue:
22(1)
Published: Oct. 28, 2024
Immune
cell
therapy
based
on
chimeric
antigen
receptor
(CAR)
technology
platform
has
been
greatly
developed.
The
types
of
CAR
immune
have
expanded
from
T
cells
to
innate
such
as
NK
and
macrophages,
the
diseases
treated
hematological
malignancies
non-tumor
fields
infectious
autoimmune
diseases.
Among
them,
CAR-T
CAR-NK
observed
examples
rapid
remission
in
approved
clinical
trials,
but
efficacy
is
unstable
plagued
by
tumor
resistance.
Trogocytosis
a
special
phenomenon
intercellular
molecular
transfer
that
common
system
achieved
recipient
through
acquisition
internalization
donor
cell-derived
molecules
mediates
effects.
Recently,
novel
short-term
drug
resistance
mechanism
trogocytosis
proposed,
bidirectional
exchange
between
triggered
partially
explains
long-term
relapse
after
treatment
with
cells.
In
this
review,
we
summarize
research
progress
immunotherapy,
discuss
influencing
factors
its
direct
indirect
interference
emphasize
can
further
release
potential
therapy.
Language: Английский
Advances in CAR NK Cell Therapy for Targeting and Eradicating Circulating Tumor Cells: Challenges and Solutions for Aging Patients Mini Review
Ageing & Longevity,
Journal Year:
2024,
Volume and Issue:
4 2024, P. 157 - 173
Published: Nov. 11, 2024
Chimeric
Antigen
Receptor
(CAR)
Natural
Killer
(NK)
cells
represent
a
promising
advancement
in
cancer
immunotherapy,
particularly
for
targeting
circulating
tumor
(CTCs)
and
preventing
metastasis.
This
review
examines
the
latest
developments
CAR
NK
cell
therapy,
including
diverse
sources,
genetic
engineering
techniques,
dual
mechanisms
of
action.
Targeting
CTCs
with
shows
significant
potential
aggressive
cancers
like
triple-negative
breast
(TNBC)
pancreatic
cancer.
The
impact
aging
on
function,
especially
regarding
cytotoxicity,
cytokine
secretion,
persistence,
poses
challenges
elderly
patients,
but
strategies
such
as
interleukin-15
metabolic
interventions
offer
solutions.
also
addresses
current
limitations,
poor
persistence
immunosuppressive
microenvironments
low
solid
infiltration,
while
proposing
combination
therapies
to
enhance
effectiveness.
Although
still
earlier
clinical
stages
compared
T
cells,
cells’
safety
profile
MHC-independent
recognition
make
them
versatile
therapeutic
option.
Future
directions
include
optimizing
improving
developing
age-adapted
patients.
_________________________________________________________________________________________
Keywords:
Circulating
(CTCs),
Cell
Therapy,
Aging
Language: Английский